文献速递瓣膜外科

观察值与预期值30天死亡率比值作为经导管主动脉瓣置换术的基准

Observed to expected 30-day mortality as a benchmark for transcatheter aortic valve replacement.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-07-27

该研究回顾性分析2008至2015年546例TAVR患者,计算基于STS-PROM的30天死亡率观察值与预期值比值(O:E比值)。总体O:E比值为0.4,显著低于1;STS-PROM持续高估TAVR术后30天死亡率。作者认为O:E比值低于0.6是所有TAVR项目的现实目标。

要点

  • TAVR术后30天死亡率O:E比值为0.4,显著低于1。
  • STS-PROM持续高估TAVR术后30天死亡率。
  • O:E比值低于0.6可作为TAVR项目的现实目标。

核心结论

  • STS-PROM持续高估TAVR术后30天死亡率。
  • O:E比值低于0.6可能是所有TAVR项目的现实目标。
  • 基于STS-PROM的O:E比值大于0.6的项目应重新评估内部流程以改善结果。

研究设计与样本

  • 前瞻性收集2008至2015年546例TAVR患者数据,并进行回顾性分析。

主要发现

  • 总体30天死亡率O:E比值为0.4,显著低于1(P < .001;95%置信区间,0.25-0.63)。
  • 低风险(STS-PROM < 4)、中风险(STS-PROM = 4-8)和高风险(STS-PROM > 8)患者的O:E比值均低于0.5。
  • 经心尖途径患者的O:E比值(0.8)显著高于经股动脉途径患者(0.2)。
  • 商业组(O:E比值 = 0.5)与研究组(O:E比值 = 0.3)的O:E比值相似(P = .337),且均显著低于1(分别为P = .007和P < .001)。

关键数值与推荐

  • 总体30天死亡率O:E比值为0.4(95%置信区间,0.25-0.63),显著低于1(P < .001)。
  • 低风险(STS-PROM < 4)、中风险(STS-PROM = 4-8)和高风险(STS-PROM > 8)患者的O:E比值均低于0.5。
  • 经心尖途径O:E比值为0.8,经股动脉途径为0.2。
  • 商业组O:E比值为0.5,研究组为0.3,两者相似(P = .337)。

临床怎么用

  • TAVR项目可使用基于STS-PROM的O:E比值作为30天死亡率的质量基准。
  • O:E比值低于0.6可作为现实目标,高于0.6的项目应重新评估内部流程。
  • 当前TVT注册研究的结果(O:E比值1.0)对于商业TAVR不可接受。

局限性

  • 数据来自单中心前瞻性收集但回顾性分析,样本量为546例。
  • 研究期间为2008至2015年,可能不能完全反映当前实践。
  • 尚缺乏准确且特异的TAVR术后30天死亡率风险计算工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The observed-to-expected 30-day mortality ratio (O:E ratio) is a standard metric by which transcatheter aortic valve replacement (TAVR) trials have been evaluated. Early TAVR trials consistently demonstrated O:E ratio less than 0.6 after TAVR when based on the Society for Thoracic Surgery Predicted Risk of Mortality (STS-PROM) for surgical aortic valve replacement. Recent published results from the Transcatheter Valve Therapy (TVT) Registry have demonstrated O:E ratios of 1.0. We evaluated our own O:E ratios for TAVR to investigate this discordance. METHODS: Data were collected prospectively for TAVR patients from 2008 through 2015 (N = 546) and were reviewed retrospectively. The observed mortality and STS-PROM were calculated to formulate O:E ratios and were compared over a variety of subgroups. RESULTS: Overall, the O:E ratio for 30-day mortality was 0.4 and significantly less than 1 (P < .001; 95% confidence interval, 0.25-0.63). The O:E ratio relationship remained less than 0.5 for patients with low (STS-PROM < 4), moderate (STS-PROM = 4-8) and high risk (STS-PROM > 8). The O:E ratio was significantly higher for transapical patients (O:E ratio = 0.8) when compared with transfemoral patients (O:E ratio = 0.2). Lastly, O:E ratios for both commercial (O:E ratio = 0.5) and research (O:E ratio = 0.3) patients were similar (P = .337), and both were significantly less than 1 (P = .007 and P < .001, respectively). CONCLUSIONS: The STS-PROM consistently overestimated 30-day mortality after TAVR. Achieving an O:E ratio less than 0.6 may be a realistic goal for all TAVR programs. While an accurate and specific risk calculator for 30-day mortality after TAVR remains to be established, our data suggest that current TVT results are not acceptable for commercial TAVR and that programs with an O:E ratio greater than 0.6, based on the STS-PROM, should reevaluate internal processes to improve their results.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Henn MC, Zajarias A, Quader N, et al. Observed to expected 30-day mortality as a benchmark for transcatheter aortic valve replacement. J Thorac Cardiovasc Surg. 2018. PMID: 30454980. doi:10.1016/j.jtcvs.2018.06.097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。